Science and technology innovation board officially announced the opening of the board, and the number of biomedical enterprises accounts for a relatively high proportion

[pharmaceutical Station industry trends] on June 13, the science and technology innovation board officially announced its opening Up to now, there are 122 companies accepting listing applications on the science and technology innovation board platform If the accepting enterprises are re divided according to the industries recommended by the science and technology innovation board, the number of enterprises in the new generation information technology field and biomedical field is relatively high, accounting for 65.3% in total According to the statistics of the industry, as of May 27, there are 16 enterprises in the biomedical industry, accounting for 14.29% of the total science and technology innovation board Science and technology innovation board attracts a large number of biomedical enterprises to enter the science and technology innovation board Biomedical industry is a typical "high input, high risk, high output, long cycle" industry, and also a sunrise industry in China According to the data, the sales revenue of China's biomedical industry increased continuously from 2009 to 2016, and maintained a rapid growth By 2017, the market scale of China's biomedical industry was 341.719 billion yuan, slowing down compared with the year-on-year growth In general, the potential of biomedical industry is still huge Among the first and second batch of enterprises applying for science and technology innovation board, 30% are from the biomedical industry, and there are also some key proposals for the Listing Rules of biomedical industry, including the requirements for R & D investment With the rapid development of science and technology innovation board, a large number of qualified biomedical companies will be attracted to the science and technology innovation board to accelerate the investment pace of biomedical industry For example, pre scientific biology, micro core biology, Tebo biology, Shenlian biology, Yuandong biology, hotscape biology, Borui biology, Huaxi biology and other biomedical enterprises are all on the acceptance list A pharmaceutical enterprise that has not yet sold its products has recently accepted the listing application of Zejing pharmaceutical scientific and technological innovation board, a domestic biological new drug R & D enterprise It is worth noting that this is a pharmaceutical enterprise that has not yet sold its products, and it is also the first enterprise to adopt the fifth set of listing standards According to the requirements of the fifth set of listing standards of science and Technology Innovation Board: the market value is expected to be no less than 4 billion yuan, the main business or products need to be approved by the relevant departments of the state, and the market space is large At present, phased results have been achieved Pharmaceutical enterprises need to have at least one core product approved to carry out phase II clinical trials, and other enterprises that meet the positioning of scientific and technological innovation board need to have obvious technical advantages and meet the corresponding conditions It is understood that at present, Zejing pharmaceutical is in the stage of new drug research and development, and its products are not on the market for sale During the three years from 2016 to 2018, the company's total operating revenue was 1511500 yuan; its net profit continued to be in the state of loss, with a total loss of 715 million yuan By the end of the first quarter of 2019, the accumulated loss has reached 885 million yuan However, from the perspective of R & D, Zejing pharmaceutical is carrying out 23 research projects of 11 innovative drugs, and the total R & D cost of the company in the reporting period has reached 390 million yuan In addition, during the reporting period, the company continued to maintain daily operations through equity financing In the future, the development of biomedical industry may be unbalanced In general, biomedical enterprises can enhance their financing ability and anti risk ability with the help of science and technology innovation board, and the biomedical market will be more active in the future However, the industry also points out that in terms of the number distribution of listed biomedical enterprises and the number of biomedical enterprises, the market competition of biomedical industry in the future will be fierce and regional disputes will be obvious However, due to the large proportion of biomedical listed enterprises in some regions, the advantages are obvious In addition, due to the different support from different regions, it is difficult to balance the development of regional biomedical industry in China in the next few years.